tradingkey.logo
搜索

Inventiva SA

IVA
添加自选
5.440USD
-0.110-1.98%
收盘 05/15, 16:00美东报价延迟15分钟
1.17B总市值
--市盈率 TTM

Inventiva SA

5.440
-0.110-1.98%

关于 Inventiva SA 公司

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Inventiva SA简介

公司代码IVA
公司名称Inventiva SA
上市日期Feb 15, 2017
CEOObenshain (Andrew)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址50 rue de Dijon
城市DAIX
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编21121
电话33380447500
网址https://inventivapharma.com/
公司代码IVA
上市日期Feb 15, 2017
CEOObenshain (Andrew)

Inventiva SA公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Eric Duranson
Mr. Eric Duranson
General Counsel
General Counsel
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 5月8日 周五
更新时间: 5月8日 周五
持股股东
股东类型
持股股东
持股股东
占比
Samsara BioCapital, LLC
2.69%
Paradigm BioCapital Advisors LP
2.07%
Deep Track Capital LP
1.64%
Adar1 Capital Management LLC
1.40%
Trails Edge Capital Partners LP
1.38%
其他
90.83%
持股股东
持股股东
占比
Samsara BioCapital, LLC
2.69%
Paradigm BioCapital Advisors LP
2.07%
Deep Track Capital LP
1.64%
Adar1 Capital Management LLC
1.40%
Trails Edge Capital Partners LP
1.38%
其他
90.83%
股东类型
持股股东
占比
Hedge Fund
9.89%
Investment Advisor/Hedge Fund
5.28%
Venture Capital
4.92%
Investment Advisor
3.97%
Private Equity
0.94%
Research Firm
0.50%
Pension Fund
0.01%
其他
74.49%

机构持股

更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
63
49.29M
25.51%
+35.58M
2025Q4
29
15.17M
10.90%
+10.19M
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Samsara BioCapital, LLC
5.19M
3.73%
--
--
Dec 31, 2025
Paradigm BioCapital Advisors LP
4.00M
2.87%
+4.00M
--
Dec 31, 2025
Deep Track Capital LP
3.16M
2.27%
+2.67M
+545.79%
Jan 23, 2026
Adar1 Capital Management LLC
2.71M
1.95%
+2.71M
--
Dec 31, 2025
Trails Edge Capital Partners LP
2.66M
1.91%
+2.66M
--
Dec 31, 2025
Millennium Management LLC
2.65M
1.91%
+2.54M
+2267.73%
Dec 31, 2025
Franklin Advisers, Inc.
2.50M
1.8%
+2.50M
--
Dec 31, 2025
SymBiosis Capital Management, LLC
2.60M
1.87%
+2.60M
--
Dec 31, 2025
UBS Financial Services, Inc.
2.64M
1.9%
+2.63M
+28881.60%
Dec 31, 2025
Caligan Partners, LP
2.00M
1.44%
+2.00M
--
Dec 31, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI